Annogen Heads to London for the Advanced Therapies Congress 2026
Annogen is excited to confirm our attendance at the upcoming Advanced Therapies Congress, scheduled for March 17th – 18th, 2026, at ExCeL London!
Annogen is heading to ESGCT 2025!
Annogen is thrilled to announce our participation in the upcoming European Society of Gene and Cell Therapy (ESGCT) conference, taking place from October 7th to 10th in Seville, Spain.
Lentitek and Annogen join forces to improve the quality and safety of T-cell therapies
A collaboration announced at the CGTI Leadership Summit aims to improve lentivirus-based CAR-T therapies by eliminating undesired transgene expression during viral vector manufacturing.
T-cell promoter data presented at CGTI Leadership Summit
Chief Strategy Officer Martijn Kelder speaks at the Cell and Gene Therapy Innovation Leadership Summit in Barcelona, revealing novel data on Annogen’s validated T-cell specific promoters.
Annogen announces successful identification of cell-specific promoters for Orchard Therapeutics’ preclinical gene therapy programs
Orchard Therapeutics and Annogen announced the successful identification of novel human promoters for use in Orchard’s pre-clinical hematopoietic stem cell (HSC) gene therapy programs.
Ascend Advanced Therapies and Annogen Collaborate to Improve AAV Production
Ascend Advanced Therapies and Annogen will combine their expertise in AAV biology, vector manufacturing and genetic engineering to improve the quality of recombinant AAV particles used in gene therapy applications.
Corteva Annogen collaborating on functional annotation to accelerate crop improvement
Corteva Agriscience™ and Annogen B.V. are working together to functionally annotate thousands of expression elements in maize.
Annogen invited to speak at CropIB 2025
Founder & CEO Joris van Arensbergen has been invited to speak at the Crop Innovation and Business (CIB) Conference in Cologne, 30 March – 1 April 2025.
UCSF, Annogen Announce Collaboration to Identify Superior Treg-Specific Promoters
Annogen and the labs of Qizhi Tang and Brian Shy at UCSF announced a collaboration to identify and characterize promoters specific for regulatory T cells (Treg).
Annogen to perform functional genome annotations for KWS to accelerate crop improvement
KWS SAAT SE & Co. KGaA and Annogen B.V. announced a partnership in which Annogen will use its FACE™ platform to functionally annotate non-coding variants of interest to KWS.
